AUTH/3651/5/22 - Complainant v Roche

Allegations about an Ocrevus website

  • Received
    30 May 2022
  • Case number
  • Applicable Code year
  • Completed
    23 May 2023
  • No breach Clause(s)
  • Additional sanctions
  • Appeal
    No appeal

Case Summary

This case related to allegations that the claim ‘generally well tolerated’ used on the landing page of the Ocrevus (ocrelizumab) website was misleading, not balanced or accurate in view of clinical trial findings of serious adverse events.

The Panel ruled no breach of the following Clauses of the 2021 Code on the basis that the claim was qualified by a list of linked aspects of the safety and tolerability profile within the immediate visual field of the claim in question which were designed to catch the reader’s eye such that it would be sufficiently clear that the claim was not unqualified and therefore not misleading or incapable of substantiation:

No Breach of Clause 2

Requirement that material must not bring
discredit upon, or reduce confidence in, the
pharmaceutical industry

No Breach of Clause 5.1

Requirement to maintain high standards

No Breach of Clause 6.1

Requirement that claims must not be misleading

No Breach of Clause 6.2

Requirement that claims must be capable of substantiation

This summary is not intended to be read in isolation.
For full details, please see the full case report below.